Medivie Therapeutic Ltd (MDVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medivie Therapeutic Ltd (MDVI) has a cash flow conversion efficiency ratio of 0.217x as of June 2021. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-966.00K ≈ $-2.59K USD) by net assets (ILA-4.46 Million ≈ $-11.95K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medivie Therapeutic Ltd - Cash Flow Conversion Efficiency Trend (2010–2020)
This chart illustrates how Medivie Therapeutic Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Medivie Therapeutic Ltd for a breakdown of total debt and financial obligations.
Medivie Therapeutic Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medivie Therapeutic Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Upsellon Brands Holdings Ltd
TA:CHR
|
0.180x |
|
Cobra Resources PLC
LSE:COBR
|
-0.102x |
|
SDCL EDGE Acquisition Corporation
NYSE:SEDA
|
-0.009x |
|
Enlivex Therapeutics Ltd
TA:ENLV
|
-0.131x |
|
SDM SE
XETRA:75S
|
0.321x |
|
CORELENS S.A. ZY -10
F:9GK
|
-0.301x |
|
SolarWorld Aktiengesellschaft
HM:SWVK
|
N/A |
|
Hepion Pharmaceuticals Inc
NASDAQ:HEPA
|
-0.125x |
Annual Cash Flow Conversion Efficiency for Medivie Therapeutic Ltd (2010–2020)
The table below shows the annual cash flow conversion efficiency of Medivie Therapeutic Ltd from 2010 to 2020. For the full company profile with market capitalisation and key ratios, see Medivie Therapeutic Ltd (MDVI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2020-12-31 | ILA3.73 Million ≈ $10.00K |
ILA-3.88 Million ≈ $-10.41K |
-1.041x | -81.64% |
| 2019-12-31 | ILA5.88 Million ≈ $15.76K |
ILA-3.37 Million ≈ $-9.03K |
-0.573x | -38.84% |
| 2018-12-31 | ILA12.18 Million ≈ $32.65K |
ILA-5.03 Million ≈ $-13.48K |
-0.413x | -127.05% |
| 2017-12-31 | ILA16.26 Million ≈ $43.60K |
ILA-2.96 Million ≈ $-7.93K |
-0.182x | +97.06% |
| 2016-12-31 | ILA577.00K ≈ $1.55K |
ILA-3.57 Million ≈ $-9.58K |
-6.194x | -192.21% |
| 2015-12-31 | ILA-527.00K ≈ $-1.41K |
ILA-3.54 Million ≈ $-9.49K |
6.717x | +605.14% |
| 2014-12-31 | ILA2.26 Million ≈ $6.05K |
ILA-3.00 Million ≈ $-8.04K |
-1.330x | -172.72% |
| 2013-12-31 | ILA-1.52 Million ≈ $-4.08K |
ILA-2.79 Million ≈ $-7.47K |
1.829x | +117.83% |
| 2012-12-31 | ILA1.22 Million ≈ $3.27K |
ILA-12.52 Million ≈ $-33.57K |
-10.254x | -172.59% |
| 2011-12-31 | ILA3.65 Million ≈ $9.80K |
ILA-13.74 Million ≈ $-36.85K |
-3.762x | -321.61% |
| 2010-12-31 | ILA-5.68 Million ≈ $-15.24K |
ILA-9.65 Million ≈ $-25.87K |
1.697x | -- |
About Medivie Therapeutic Ltd
Medivie Therapeutic Limited develops and markets dental devices. It offers Laboraide, a dental device that is placed between the woman's lower and upper jaw during birth, which allows the relaxation of the jaw, neck, and head muscles through the flow of oxygen to the muscles. The company also develops modular pacifiers that enables development of mouth structure and prevent future damage to the c… Read more